| Biological oxidations | R-HSA-211859 | 5.55 |
| G alpha (i) signalling events | R-HSA-418594 | 5.1 |
| Peptide ligand-binding receptors | R-HSA-375276 | 5.41 |
| Metabolism | R-HSA-1430728 | 2.34 |
| G alpha (s) signalling events | R-HSA-418555 | 5.99 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 7.85 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 7.08 |
| Peptide hormone metabolism | R-HSA-2980736 | 6.61 |
| Disease | R-HSA-1643685 | 3.33 |
| Peptide hormone biosynthesis | R-HSA-209952 | 9.4 |
| Metabolism of lipids and lipoproteins | R-HSA-556833 | 3.79 |
| GPCR ligand binding | R-HSA-500792 | 4.19 |
| Metabolism of steroid hormones and vitamin D | R-HSA-196071 | 7.89 |
| GPCR downstream signaling | R-HSA-388396 | 3.07 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 4.69 |
| Metabolism of proteins | R-HSA-392499 | 3.41 |
| Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD) | R-HSA-5579031 | 11.98 |
| Phase 1 - Functionalization of compounds | R-HSA-211945 | 6.7 |
| Androgen biosynthesis | R-HSA-193048 | 9.52 |
| Glucocorticoid biosynthesis | R-HSA-194002 | 9.81 |
| Signaling by GPCR | R-HSA-372790 | 2.68 |
| Opioid Signalling | R-HSA-111885 | 6.64 |
| G-protein activation | R-HSA-202040 | 8.18 |
| Diseases of metabolism | R-HSA-5668914 | 6.57 |
| Endogenous sterols | R-HSA-211976 | 8.46 |
| Signal Transduction | R-HSA-162582 | 1.78 |